Mentioned:
Enhanced Group wants to be a major player in prescription peptides. And now, they’ve just launched access to six more popular compounds.
What’s happening:
- Enhanced Group (NYSE: ENHA) has launched access to six additional peptides through licensed clinicians
Why it matters:
- BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax are now all available for prescription through Enhanced Group’s platform
Going deeper:
- Enhanced Group’s peptides are currently available to be prescribed to adults in the United States, with eligibility varying on a state by state basis
- Enhanced Group now has a total of eight different peptides available for prescription through licensed clinicians
The intrigue:
- Billionaire investor and entrepreneur Christian Angermayer previously made waves when he led a $50M USD financing round into Enhanced Group through his family office Apeiron Investment Group
